A novel whole-blood miRNA signature for a rapid diagnosis of pulmonary tuberculosis

Latorre, Irene; Leidinger, Petra; Backes, Christina; Domínguez, J.; Souza-Galvão, Maria Luiza de; Maldonado, José; Prat, Cristina; Ruiz-Manzano, Juan; Sánchez, Francisca; Casas, Irma; Keller, Andreas; Briesen, Hagen von; Knobel, Hernando; Meese, Eckart; Meyerhans, Andreas

doi:10.1183/09031936.00221514

Cited by 53 publications

(42 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results shows that hsa‐miR‐223‐3p has down‐regulated and the inflammatory response pathway has been highly activated according to IPA core analysis and the molecule function analysis shows that in the inflammatory response module, although immune response and antiviral response parts are highly activated, the inflammation part is inhibited in an overall level. However, a study has shown that hsa‐miR‐223 is up‐regulated in patients with tuberculosis (no more than 2 weeks of chemoprophylaxis), while there is no significant change in patients with latent tuberculosis . It is speculated that the differential expression level of miR‐223 might be related to the differences in the infected TB strains .…”

Section: Discussionmentioning

confidence: 99%

STAT1 and its related molecules as potential biomarkers in Mycobacterium tuberculosis infection

Zhang

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

Tuberculosis (TB) is a severe infectious disease that seriously endangers human health. The immune defence mechanism of the body against TB is still unclear. The purpose of this study was to find the key molecules involved in the immune defence response during TB infection, and provide reference for the treatment of TB and further understanding of the immune defence mechanism of the body. Data from http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE83456 were downloaded from GEO data sets for analysis, and a total of 192 differentially expressed genes were screened out. Most of these genes are enriched in the interferon signalling pathway and are defence response–related. We also found that STAT1 plays an important role in the immune defence of TB infection and it is one of the key genes related to interferon signalling pathway. STAT1‐related molecules including hsa‐miR‐448, hsa‐miR‐223‐3p, SAMD8_hsa_circRNA 994 and TWF1_hsa_circRNA 9897 were therefore screened out. Furthermore, expression levels of hsa‐miR‐448 and hsa‐miR‐223‐3p were then verified by qRT‐PCR. Results showed that both hsa‐miR‐448 and hsa‐miR‐223‐3p were down‐regulated in plasma from patients with pulmonary TB. Taken together, our data indicate that an mRNA‐miRNA‐circRNA interaction chain may play an important role in the infection of MTB, and STAT1 and related molecules including hsa‐miR‐223‐3p, has‐miR‐448, SAMD8_hsa_circRNA994 and TWF1_hsa_circRNA9897 were identified as potential biomarkers in the development of active TB.

show abstract

Section: Discussionmentioning

confidence: 99%

STAT1 and its related molecules as potential biomarkers in Mycobacterium tuberculosis infection

Zhang

et al. 2020

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…miRNA signatures are frequently generated by high-throughput approaches such as microarray or parallel sequencing followed by low-to medium throughput validation using, for example, RT-qPCR. We, and others, have performed casecontrol studies for various diseases, including Alzheimer's disease [45], heart failure [43], tuberculosis [64], pancreatic cancer [65], multiple sclerosis [66], neuromyelitis optica [67], lung cancer [68], and melanoma [69,70]. Following the discovery phase, there are currently several studies underway to validate miRNA signatures in independent cohorts.…”

Section: Mirna Signaturesmentioning

confidence: 97%

Specific miRNA Disease Biomarkers in Blood, Serum and Plasma: Challenges and Prospects

2016

Self Cite

View full text Add to dashboard Cite

Significant effort has been devoted to discovering microRNA (miRNA) disease biomarkers. In particular, miRNAs in whole blood or specific blood components are candidates for improving the diagnosis of diseases, including life-threatening pathologies. This review covers the challenges crucial for the translation of miRNAs in body fluids (circulating miRNAs) from a research setting into a clinical care scenario. First, we discuss the specificity of miRNA biomarkers for the diagnosis of a disease. While single miRNAs such as miR-20a, miR-21, miR-155, and miR-126 are frequently not disease specific, miRNA signatures that consist of a plurality of different miRNAs may help to improve differentiation between pathologies. Second, we discuss the degree of reproducibility and highlight selected validation studies. While single miRNA markers are often confirmed by independent studies, miRNA signatures are less frequently verified. Third, we address challenges to the profiling of miRNAs in high-throughput settings and we discuss the appropriateness of various analytical platforms and bioinformatics towards a clinical application of miRNAs. Finally, we shed light on the suitability of enriched miRNA sources, e.g. fractionation of body fluids for extracellular vesicles such as exosomes or blood cells, to develop miRNA signatures. With an increasing number of verified miRNA signatures and with the advance of matured medium-throughput approaches in clinical settings, specific miRNA markers are increasingly likely to contribute to human healthcare.

show abstract

“…Similarly, multiple studies of the Mycobacterium tuberculosis microRNAome have yielded numerous biomarkers that are currently being explored for diagnostic purposes 83 and even for phenotype-genotype predictive diagnostics (such as for identifying the presence of multi-drug resistance) 84 .…”

Section: Companion Diagnosticmentioning

confidence: 99%

Translating RNA sequencing into clinical diagnostics: opportunities and challenges

et al. 2016

View full text Add to dashboard Cite

With the emergence of RNA sequencing (RNA-seq) technologies, RNA-based biomolecules hold expanded promise for their diagnostic, prognostic and therapeutic applicability in various diseases, including cancers and infectious diseases. Detection of gene fusions and differential expression of known disease-causing transcripts by RNA-seq represent some of the most immediate opportunities. However, it is the diversity of RNA species detected through RNA-seq that holds new promise for the multi-faceted clinical applicability of RNA-based measures, including the potential of extracellular RNAs as non-invasive diagnostic indicators of disease. Ongoing efforts towards the establishment of benchmark standards, assay optimization for clinical conditions and demonstration of assay reproducibility are required to expand the clinical utility of RNA-seq.

show abstract

A novel whole-blood miRNA signature for a rapid diagnosis of pulmonary tuberculosis

Cited by 53 publications

References 15 publications

STAT1 and its related molecules as potential biomarkers in Mycobacterium tuberculosis infection

STAT1 and its related molecules as potential biomarkers in Mycobacterium tuberculosis infection

Specific miRNA Disease Biomarkers in Blood, Serum and Plasma: Challenges and Prospects

Translating RNA sequencing into clinical diagnostics: opportunities and challenges

Contact Info

Product

Resources

About